Harrow (HROW) beats earnings and revenue estimates, stock performance hinges on future guidance

From Nasdaq: 2025-03-27 18:45:00

Harrow (HROW) reported quarterly earnings of $0.25 per share, surpassing the Zacks Consensus Estimate of $0.11. This marks an improvement from a loss of $0.27 per share a year ago. The pharmaceutical company exceeded revenue expectations with $66.83 million, higher than the previous year’s $36.36 million.

The company has beaten consensus EPS estimates twice in the last four quarters. Despite a recent stock decline of 17.6%, Harrow’s future performance hinges on management’s guidance. Analysts are closely watching earnings estimates and revenue outlook for the coming quarters, with a Zacks Rank #3 (Hold) currently assigned to the stock.

Elevance Health (ELV) is yet to disclose its March 2025 quarter results. Expectations are set at $10.60 per share in earnings, a slight decrease from the prior year. Revenue projections stand at $45.74 billion, reflecting an 8.2% increase from the same period last year. Investors should monitor industry trends for potential impacts on stock performance.



Read more at Nasdaq: Harrow (HROW) Q4 Earnings and Revenues Top Estimates